Tilray Medical Launches Redecan Cannabis Brand in Australia
EU-GMP Certified Redecan Cannabis Now Available in
Australia with Medical Prescription
NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) --
Tilray Medical, a division of Tilray Brands,
Inc. ("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a
global leader in medical cannabis, empowering the therapeutic
alliance between patients and healthcare practitioners to make
informed individualized health decisions, today announced the
launch of Redecan EU-GMP certified medical cannabis products
in Australia.
Denise Faltischek, Chief Strategy Officer and
Head of International, Tilray Brands, said, “The launch of Redecan,
a premium cannabis brand, in Australia is another significant
milestone for Tilray Medical, as we relentlessly pursue our vision
of making high-quality medical cannabis products accessible to
patients worldwide. The launch of Redecan further expands our
medical cannabis portfolios alongside our current Tilray and Broken
Coast offerings, as we continue our mission of empowering patients
and healthcare practitioners to find the optimal therapeutic
solutions.”
Jonathan Trodden, Director, Tilray Medical
Australia, adds: “We are proud to launch Redecan in Australia and
further strengthen our ongoing commitment to providing patients
with a consistent, accessible supply of premium quality medical
cannabis to choose from.”
The following Redecan products are now
available for medical cannabis patients in Australia:
- Redecan PC THC28 Purple Churro – 15g
- Redecan SA THC28 Space Age Cake – 15g
Tilray continues to be one of the leading
providers of EU-GMP certified medical cannabis to patients,
physicians, pharmacies, hospitals, governments, and researchers
across the globe, and today offers a comprehensive portfolio of THC
and CBD products in over 20 countries. In furtherance of its
mission, Tilray has supported medical trials globally
studying the efficacy of medical cannabis as a treatment for
indications including fibromyalgia, pediatric epilepsy, refractory
pediatric epilepsy, cancer-induced nausea and vomiting, HIV,
essential tremor, breast cancer disorders, post-traumatic stress
disorder, and alcohol use disorders.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering
dignity for patients in need through safe and reliable access to a
global portfolio of medical cannabis brands,
including Tilray, Aphria, Broken Coast, Symbios and
Navcora. Tilray grew from being one of the first
companies to become an approved licensed producer of medical
cannabis in Canada to building the first EU-GMP certified
cannabis production facilities in Europe, specifically
in Portugal and Germany simultaneously. Today,
Tilray Medical is one of the largest suppliers of medical cannabis
to patients, physicians, hospitals, pharmacies, researchers, and
governments in 20 countries and across five continents.
For more information on Tilray Medical,
visit Tilray Medical Europe, Tilray Medical Canada,
and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a
leading global lifestyle and consumer packaged goods company with
operations in Canada, the United States, Europe, Australia, and
Latin America that is leading as a transformative force at the
nexus of cannabis, beverage, wellness, and entertainment, elevating
lives through moments of connection. Tilray’s mission is to be a
leading premium lifestyle company with a house of brands and
innovative products that inspire joy and create memorable
experiences. Tilray’s unprecedented platform supports over 40
brands in over 20 countries, including comprehensive cannabis
offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating
lives through moments of connection, visit Tilray.com and follow
@Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical
facts constitute forward-looking information or forward-looking
statements (together, “forward-looking statements”) under Canadian
and U.S. securities laws and within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, that are
intended to be subject to the “safe harbor” created by those
sections and other applicable laws. Forward-looking statements can
be identified by words such as “forecast,” “future,” “should,”
“could,” “enable,” “potential,” “contemplate,” “believe,”
“anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,”
“project,” “will,” “would” and the negative of these terms or
similar expressions, although not all forward-looking statements
contain these identifying words. Certain material factors,
estimates, goals, projections, or assumptions were used in drawing
the conclusions contained in the forward-looking statements
throughout this communication. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses, or current expectations. Many factors could cause actual
results, performance, or achievement to be materially different
from any forward-looking statements, and other risks and
uncertainties not presently known to the Company or that the
Company deems immaterial could also cause actual results or events
to differ materially from those expressed in the forward-looking
statements contained herein. For a more detailed discussion of
these risks and other factors, see the most recently filed annual
information form of Tilray and the Annual Report on Form
10-K (and other periodic reports filed with the SEC)
of Tilray made with the SEC and available on
EDGAR. The forward-looking statements included in this
communication are made as of the date of this communication and the
Company does not undertake any obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events, or otherwise unless required by applicable securities
laws.
For further information, please
contact:
Media: news@tilray.com
Investors: investors@tilray.com
Tilray Brands (TG:2HQ)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Tilray Brands (TG:2HQ)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
